Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients
- PMID: 30056534
- DOI: 10.1007/s12640-018-9937-8
Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients
Abstract
Eotaxin is increased in neurodegenerative disorders and schizophrenia, and preclinical studies indicate that eotaxin may induce cognitive deficits. This study aims to examine whether peripheral levels of eotaxin impact cognitive functioning in healthy volunteers and formal thought disorder (FTD) and psychopathology in schizophrenia patients. Serum levels of eotaxin were assayed and cognitive tests were performed on a sample of 40 healthy participants and 80 schizophrenia patients. Among healthy participants, eotaxin levels were significantly associated with episodic/semantic memory, executive functions, Mini Mental State Examination, emotion recognition, and sustained attention. In addition, age-related effects on these cognitive measures were partly mediated by eotaxin. The super-variable "age-eotaxin" predicted a large part of the variance in cognitive functions among healthy participants, and hence, eotaxin may act as an "accelerated brain aging chemokine" (ABAC). In schizophrenia, eotaxin levels had a strong impact on formal thought disorders and psychopathology. In schizophrenia, increased eotaxin strongly impacts memory and sustained attention, which together to a large extent determine FTD. FTD together with memory deficits predicts around 92.5% of the variance in psychopathology. Moreover, the effects of eotaxin are partially mediated by executive functioning, while the effects of male sex on FTD and psychopathology are mediated by eotaxin. In healthy subjects, eotaxin strongly impacts executive functioning and multiple cognitive domains. In schizophrenia, peripheral levels of eotaxin strongly impact both negative symptoms and psychosis (hallucinations and delusions), and these eotaxin effects are mediated by impairments in frontal functioning, memory, sustained attention, and FTD. Eotaxin is an endogenous cognitive deteriorating chemokine (ECDC) and a novel therapeutic target for age-related cognitive decline and schizophrenia as well.
Keywords: Cytokines; Immune; Inflammation; Interleukin; Neurocognition; Schizophrenia.
Similar articles
-
Cognitive deficits and its relation with psychopathology and global functioning in first episode schizophrenia.Asian J Psychiatr. 2013 Dec;6(6):537-43. doi: 10.1016/j.ajp.2013.07.002. Epub 2013 Aug 13. Asian J Psychiatr. 2013. PMID: 24309868
-
CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders.Pharmaceuticals (Basel). 2020 Sep 2;13(9):230. doi: 10.3390/ph13090230. Pharmaceuticals (Basel). 2020. PMID: 32887304 Free PMC article. Review.
-
High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.Schizophr Bull. 2021 Mar 16;47(2):530-541. doi: 10.1093/schbul/sbaa136. Schizophr Bull. 2021. PMID: 32971537 Free PMC article.
-
The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.CNS Neurol Disord Drug Targets. 2018;17(6):473-486. doi: 10.2174/1871527317666180702160921. CNS Neurol Disord Drug Targets. 2018. PMID: 29968545
-
[Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].Encephale. 2013 May;39 Suppl 1:S64-71. doi: 10.1016/j.encep.2012.10.011. Epub 2013 Mar 23. Encephale. 2013. PMID: 23528322 Review. French.
Cited by
-
Differences in Eotaxin Serum Levels between Polytraumatized Patients with and without Concomitant Traumatic Brain Injury-A Matched Pair Analysis.J Clin Med. 2024 Jul 19;13(14):4218. doi: 10.3390/jcm13144218. J Clin Med. 2024. PMID: 39064258 Free PMC article.
-
Blood-based therapies to combat neurodegenerative diseases.Metab Brain Dis. 2024 Jun;39(5):985-1004. doi: 10.1007/s11011-024-01368-x. Epub 2024 Jun 6. Metab Brain Dis. 2024. PMID: 38842660 Review.
-
Differences in mid-gestational and early postnatal neonatal cytokines and chemokines are associated with patterns of maternal autoantibodies in the context of autism.Cereb Cortex. 2024 May 2;34(13):50-62. doi: 10.1093/cercor/bhae082. Cereb Cortex. 2024. PMID: 38696596
-
Decreased IL-4 is the risk factor of depression in patients with Takayasu arteritis.Front Med (Lausanne). 2024 Feb 15;11:1337206. doi: 10.3389/fmed.2024.1337206. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38426163 Free PMC article.
-
CCR3 Expression in Relation to Delayed Microbleeds in a Rat Model of Large Vessel Occlusion.J Exp Neurol. 2024;5(1):1-8. doi: 10.33696/neurol.5.082. J Exp Neurol. 2024. PMID: 38332938 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical